Welcome to our dedicated page for Agilent Technologies SEC filings (Ticker: A), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
analytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.Agilent Technologies (A) reported condensed, unaudited quarterly results for the three and nine months ended July 31, 2025, prepared under U.S. GAAP and recast to reflect a new three-segment structure: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.
Services and other revenue grew 11% for the quarter and 9% year-to-date, driven by contract repair, preventative maintenance and on-demand services. Income from operations rose $4 million (3%) for the quarter and $21 million (6%) year-to-date on revenue increases, while operating margins faced near-term pressure from increased tariffs, shipping costs, unfavorable mix, warranty and variable pay. No goodwill impairment was indicated after quantitative testing. The company repurchased shares under its repurchase programs and paid quarterly dividends; commercial paper outstanding was $55 million at a 4.55% weighted average rate.
Agilent Technologies (A) Form 144 notice shows a proposed sale of 28,081 common shares via Fidelity Brokerage Services on the NYSE with an aggregate market value of $3,508,993.30. The filing lists two option-originated lots: 22,898 shares from an option granted 11/17/2020 and 5,183 shares from an option granted 11/22/2023, both indicated as to be sold on 08/29/2025 for cash. The filer reports 284,064,728 shares outstanding and no sales by the same person in the past three months. The notice contains the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Agilent Technologies Inc. (A) Form 144 shows a proposed sale of 21,644 common shares through Fidelity Brokerage Services with an aggregate market value of $2,706,365.76. The shares represent a small fraction of the 284,064,728 shares outstanding and the approximate sale date is 08/29/2025 on the NYSE. The shares to be sold were acquired upon option exercises dated 11/17/2020, 05/03/2022, and 11/22/2023, and payment is indicated as cash. The filer states there are no undisclosed material adverse facts and reports no securities sold in the past three months.
Agilent Technologies filed a Form 8-K reporting that on August 27, 2025 it issued a press release announcing financial results for the third fiscal quarter ended July 31, 2025. The filing states the press release is attached as Exhibit 99.1 and that the Exhibit is furnished, not "filed." The company explains it provides non-GAAP financial measures to supplement GAAP results, saying these measures exclude items such as restructuring and amortization and are used by management to evaluate segment and enterprise performance. The filing notes non-GAAP reconciliations and additional explanation appear in Exhibit 99.1.
Agilent Technologies reported the resignation of Robert W. McMahon from his role as Senior Vice President and Chief Financial Officer and named Rodney Gonsalves as interim Chief Financial Officer and interim Principal Financial Officer.
The Compensation Committee approved a bi-weekly salary stipend of $8,654 effective July 31, 2025 while Mr. Gonsalves serves as interim CFO and a grant of restricted stock units in a target amount of $1,000,000, subject to Agilent's standard equity award terms under its 2018 Stock Plan.
Agilent Technologies (NYSE: A) filed an 8-K disclosing that Chief Financial Officer Robert W. McMahon will resign effective 31 July 2025. The company states the departure is not linked to any disagreement over accounting, financial statements, internal controls, or operations.
The board has appointed Rodney Gonsalves—currently Vice President, Corporate Controller and Principal Accounting Officer—as interim CFO and Principal Financial Officer, also effective 31 July 2025. Gonsalves will retain his existing positions, and the filing notes no related-party transactions requiring disclosure under Regulation S-K Item 404(a).
A press release announcing the leadership change was issued on 15 July 2025 and furnished as Exhibit 99.1. Apart from the management transition, the filing contains no financial updates, guidance revisions, or strategic transactions.
FAQ
What is the current stock price of Agilent Technologies (A)?
What is the market cap of Agilent Technologies (A)?
